Three South Indian MedTech Startups Win a Week in Israel Through HealthSprint 2026

Three South Indian medtech startups just won a free trip to Israel — and a shot at global healthcare markets.

The Programme

HealthSprint 2026 is a joint initiative of the Consulate General of Israel in Bengaluru and Bengaluru-based accelerator GINSERV, built as a 30-day Indo-Israel innovation sprint for healthcare and medtech startups. GINSERV itself is a DST-backed incubator, operating under programmes including DST-TBI and NIDHI-SSS, and has run accelerator cohorts in Bengaluru for over a decade.

This year's edition drew 175 applications, from which 15 startups — five each across three categories, Diagnose, Treat and Manage — were shortlisted to pitch before a panel of investors, mentors and industry experts from both India and Israel.

The Winners

Three startups came out on top:

• BioCipher Labs (Bengaluru) — building AI-powered molecular diagnostics tools aimed at faster, cheaper disease detection.
• Prodancy (Bengaluru) — developer of an indigenous surgical helmet used in joint-replacement procedures, designed to cut hospitals' reliance on imported single-use consumables.
• Mykare.ai (Kochi) — an AI-native patient management platform built for clinics and smaller hospitals that typically can't afford enterprise hospital software.

All three will receive a fully funded, week-long immersive programme in Israel, where they'll engage directly with the country's healthcare and innovation ecosystem — one of the densest concentrations of digital-health and medtech startups per capita anywhere in the world — and explore partnerships to validate and scale their products internationally.

Why the Category Split Matters

The Diagnose-Treat-Manage framing isn't incidental. It maps onto three distinct bottlenecks in Indian healthcare delivery: getting an accurate diagnosis quickly and cheaply (BioCipher Labs' territory), reducing the cost and import-dependence of surgical hardware (Prodancy), and giving under-resourced clinics software that large hospital chains take for granted (Mykare.ai). Selecting one winner from each bucket, rather than picking three diagnostics plays or three device companies, suggests the programme is deliberately trying to build a portfolio that touches the whole patient journey rather than optimising for a single hot category.

The Bigger Picture

HealthSprint is a small programme by funding standards — no cheque changes hands, just mentorship, market access and a week in Tel Aviv — but it fits a pattern in Indian medtech where the scarce resource isn't capital so much as a credible path to global validation. Indian device-makers have historically struggled to get regulatory and clinical credibility recognised outside the domestic market, even when the underlying engineering is sound. Programmes that plug early-stage companies directly into a foreign country's clinical and investor networks — rather than simply handing out grant money — are a comparatively cheap way for both governments involved to test whether that gap can be closed faster through relationships than through capital alone.

For Prodancy in particular, the stakes are concrete: an indigenous surgical helmet that can displace an imported consumable is exactly the kind of import-substitution story India's broader medtech policy push — including the PRIP scheme's focus on novel medical devices — is trying to manufacture more of.

A Small Programme in a Crowded Field

HealthSprint's scale is modest next to the government-backed schemes now competing for the same category of startup — the Department of Pharmaceuticals' PRIP scheme offers up to ₹100 crore per project, and the RDI Fund has committed over ₹2,000 crore of patient capital across sectors including biotech. What HealthSprint offers instead is speed and specificity: a 30-day sprint rather than a multi-month grant cycle, and a narrowly targeted outcome — introductions into one specific foreign healthcare market — rather than broad-based capital that a startup then has to figure out how to deploy internationally on its own.

That narrowness is arguably the point. Bilateral, sector-specific accelerators like this one are cheap for both governments to run and easy to repeat annually, which means their real value compounds only if India keeps sending fresh cohorts through and Israeli partners keep finding genuine commercial fits for them — rather than the programme becoming an annual ceremony that generates headlines without follow-on deals.

What to Watch

The clearest signal of whether HealthSprint is working will come from what happens after the Israel trip ends: whether BioCipher Labs, Prodancy or Mykare.ai land an actual pilot, distribution partnership or investment out of their week in-country, or whether the exposure fades once the cohort returns home. Indian accelerator programmes with international components have a mixed record on that front, and a fourth edition of HealthSprint next year — assuming this one delivers a tangible follow-on deal for at least one winner — would be the strongest evidence yet that the model is worth scaling rather than repeating as a one-off goodwill exercise.

Sources

• Three South Indian medtech startups win HealthSprint 2026
• GINSERV — Programs, Eligibility & How to Apply
• Consulate General of Israel, Bengaluru
• GINSERV — Startup Incubator and Accelerator in Bengaluru